Skip to main content

A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.

Publication ,  Journal Article
Hussain, M; Rathkopf, DE; Liu, G; Armstrong, AJ; Kelly, WK; Ferrari, AC; Hainsworth, JD; Yang, L; Schwartz, JD; Higano, CS
Published in: JOURNAL OF CLINICAL ONCOLOGY
February 10, 2012

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 10, 2012

Volume

30

Issue

5

Publisher

AMER SOC CLINICAL ONCOLOGY

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hussain, M., Rathkopf, D. E., Liu, G., Armstrong, A. J., Kelly, W. K., Ferrari, A. C., … Higano, C. S. (2012). A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. JOURNAL OF CLINICAL ONCOLOGY, 30(5). https://doi.org/10.1200/jco.2012.30.5_suppl.97
Hussain, Maha, Dana E. Rathkopf, Glenn Liu, Andrew J. Armstrong, William Kevin Kelly, Anna C. Ferrari, John D. Hainsworth, Ling Yang, Jonathan D. Schwartz, and Celestia S. Higano. “A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.JOURNAL OF CLINICAL ONCOLOGY 30, no. 5 (February 10, 2012). https://doi.org/10.1200/jco.2012.30.5_suppl.97.
Hussain M, Rathkopf DE, Liu G, Armstrong AJ, Kelly WK, Ferrari AC, Hainsworth JD, Yang L, Schwartz JD, Higano CS. A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012 Feb 10;30(5).

Published In

JOURNAL OF CLINICAL ONCOLOGY

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 10, 2012

Volume

30

Issue

5

Publisher

AMER SOC CLINICAL ONCOLOGY

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences